Purdue Pharma L.p.

Shionogi Company Limited

Nitto-denko Corporation

Axikin Pharmaceuticals, Inc.

Naoki Tsuno

Jiangchao Yao

Katsunori Takada

Hiroyuki Takao

Hiroki Kuramoto

Kouki Fuchino

Kazuhiro Ikai

R Richard Goehring

Xiaoming Zhou

Bin Shao

Yoshiyuki Taoda

Hidenori Mikamiyama

Akira Matsumura

Tatsuhiko Ueno

John W F Whitehead

John William Frank Whitehead

Moriyasu Masui

Klaus Urbahns

Toru Umemoto

Kevin Brown

Kevin Bacon

Toshiya Moriwaki

Nagahiro Yoshida

Daisuke Hamamoto

Hiromi Sugimoto

Yingfu Li

Keiko Fukushima

Noriko Nunami

Shinya Hiraoka

Naoki Hashimoto

Makiko Marumo

Kentaro Hashimoto

Laykea Tafesse

Nobuyuki Tanaka

Shinji Suzuki

Makoto Adachi

Motoki Haishi

Akira Yukimasa

Hiroki Yamaguchi

Dawit Tadesse

Motohiro Fujiu

Takatsugu Inoue

Hiroki Ozawa

Richard R Goehring

Yusuke Ichihashi

Jeffrey Michael Marra

Yoshiyasu Baba

Ronnie Ortiz

David Igo

Naoki Miyake

Mayu Fukuda

Hiromi Kudo

Kevin C Brown

Provided herein are novel crystalline forms of a crystalline compound of Formula (I), which modulates the ORL-1 receptor. The crystalline compounds of Formula (I), compositions thereof, and methods of using thereof that are described herein are particularly useful for treatment, prevention, and management of several sleep disorders.

Polymorphic forms of a substituted-quinoxaline-type bridged-piperidine compound

The invention relates to Substituted-Quinoxaline-Type Bridged-Piperidine Compounds, compositions comprising an effective amount of a Substituted-Quinoxaline-Type Bridged-Piperidine Compound and methods to treat or prevent a condition, such as pain, comprising administering to an animal in need thereof an effective amount of a Substituted-Quinoxaline-Type Bridged-Piperidine Compound.

Pharmaceutical salts of substituted-quinoxaline-type bridged-piperidine compounds

Compounds of Formula (I): where R, R, R, a, and b are disclosed herein, and pharmaceutically acceptable derivatives thereof, compositions thereof, and methods to treat or prevent a condition (such as pain) thereof. The disclosure also provides compounds of formula QB or O2 and their utility in manufacture processes in obtaining compounds of Formula (I).

9'-Aza[3,9&#x2032;-bi(bicyclo[3.3.1]nonan)]-3&#x2032;-one and preparation thereof

Provided are: a transparent electroconductive film with good transparency, wherein the transparent electroconductive film has antiblocking properties that can withstand roll-to-roll manufacturing, and white haze on the transparent electroconductive film side is reduced. Also provided is a touch sensor in which the transparent electroconductive film is used. This transparent electroconductive film includes a transparent substrateand a transparent electroconductive filmformed on one side of the transparent substrate, wherein the arithmetic mean surface roughness Ra in a 452&#xd7;595 &#x3bc;m field of view on the surface of the transparent electroconductive filmis greater than 0 nm and no more than 10 nm, and the arithmetic mean surface roughness Ra in a 452&#xd7;595 &#x3bc;m field of view on the surface of the transparent substrateon which the transparent electroconductive filmis not formed is greater than 5 nm and less than 100 nm.

Transparent electroconductive film and touch sensor in which same is used

The disclosure relates to Substituted Piperidin-4-amino-Type Compounds of Formula (I) and pharmaceutically acceptable salts and solvates thereof wherein R, R, R, Q, Q, E, E, A, B, D, W, Z, a, b, n, and x are as defined herein, compositions comprising an effective amount of a Substituted Piperidin-4-amino-Type Compound, and methods to treat or prevent a condition, such as pain, comprising administering to an animal in need thereof an effective amount of a Substituted Piperidin-4-amino-Type Compound. 

Substituted piperidin-4-amino-type compounds and uses thereof

Compounds of Formula (I): where R, R, R, a, and b are disclosed herein, and pharmaceutically acceptable derivatives thereof (a 'Substituted-Quinoxaline-Type Bridged-Piperidine Compound'), compositions comprising an effective amount of a Substituted-Quinoxaline-Type Bridged-Piperidine Compound, and methods to treat or prevent a condition, such as pain, comprising administering to an animal in need thereof an effective amount of a Substituted-Quinoxaline-Type Bridged-Piperidine Compound.

Substituted-quinoxaline-type bridged-piperidine compounds as ORL-1 modulators

Provided are a double-sided transparent conductive film which has blocking resistance and a low reflectance, and is inhibited from scattering reflected light to exhibit good visibility; a roll thereof; and a touch panel. The double-sided transparent conductive film of the present invention includes a base material film with an optical adjusting layer laminate and a transparent conductive layer formed in this order on each of both sides, the optical adjusting layer laminate including two or more optical adjusting layers, wherein the optical adjusting layers have different refractive indexes in each of the optical adjusting layer laminates, an anti-blocking layer containing particles is formed between the base material film and at least one of the optical adjusting layer laminates, the anti-blocking layer includes a flat portion, and a protrusion portion resulting from the particles, a value obtained by subtracting a value of a thickness of the flat portion of the anti-blocking layer from a value of a mode diameter of the particles is larger than a value of a thickness of the optical adjusting layer laminate, and the optical adjusting layer laminates each have a thickness of not less than 60 nm and not more than 250 nm.

Double-sided transparent conductive film and touch panel

The present invention is related to a compound represented by formula (I) wherein &#x2014;X&#x2014; is &#x2014;NH&#x2014; or &#x2014;S&#x2014;; &#x2014;Z&#x2014; is &#x2014;O&#x2014; or &#x2014;S&#x2014;; R, Rand Rare each independently a hydrogen atom, substituted or unsubstituted alkyl, or the like; Ris a cyano, substituted or unsubstituted amino, or the like; Ris each independently a halogen; b is 0 or 1; or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising thereof.

Aromatic heterocyclylamine derivative having TRPV4-inhibiting activity

A double-sided transparent conductive film including a base material film, having an anti-blocking layer, an optical adjusting layer and a transparent conductive layer formed in this order on each of both sides of the base material film, wherein an anti-blocking layer containing particles is formed at least one of: a location between the base material film and one optical adjusting layer; and a location between the base material film and the other optical adjusting layer, the anti-blocking layer has a flat portion and protrusion portions caused by the particles, and a value obtained by subtracting a thickness of the flat portion of the anti-blocking layer from a mode diameter of the particles is larger than a thickness of the optical adjusting layer.

A transparent conductive film includes a film base, a cured resin layer formed at one side of the film base, and an indium composite oxide layer laminated at a side of the cured resin layer opposite to the film base. The indium composite oxide layer has a thickness of 20 nm to 50 nm. The cured resin layer has a plurality of spherical particles and a binder resin layer which fixes the plurality of spherical particles to the film base. A difference w&#x2212;d between a mode particle size w and a thickness d of the binder resin layer is greater than zero and less than or equal to 1.2 &#x3bc;m, where w is a mode particle size of the spherical particles and d is a thickness of the binder resin layer.

Transparent conductive film

The invention relates to Substituted-Quinoxaline-Type Piperidine Compounds, compositions comprising an effective amount of a Substituted-Quinoxaline-Type Piperidine Compound and methods to treat or prevent a condition, such as pain, comprising administering to an animal in need thereof an effective amount of a Substituted-Quinoxaline-Type Piperidine Compound.

Substituted-quinoxaline-type piperidine compounds and the uses thereof

The disclosure relates to Azetidine-Substituted Quinoxaline-Type Piperidine Compounds of Formula (I): and pharmaceutically acceptable derivatives thereof wherein the R, R, R, Q, Y, Z, A, B, a, and b are as defined herein, compositions comprising an effective amount of an Azetidine-Substituted Quinoxaline-Type Piperidine Compound, and methods to treat or prevent a condition, such as pain, comprising administering to an animal in need thereof an effective amount of an Azetidine-Substituted Quinoxaline-Type Piperidine Compound.

Azetidine-substituted quinoxalines as opioid receptor like-1 modulators

A hard-coated antiglare film that has superior antiglare properties, allow high definition to be provided even in the case of a low haze value, can prevent white blur in an oblique direction from occurring and, and can improve the depth of black in black display, as well as a polarizing plate, and the like. The hard-coated antiglare film includes a transparent plastic film substrate and a hard-coating antiglare layer containing fine particles, which is on at least one surface of the transparent plastic film substrate. The hard-coated antiglare film has a total haze value Ht in the range of 10% to 35%. The total haze value Ht and an internal haze value Hin satisfy a relationship of 0.5&#x2266;Hin/Ht&#x2266;0.9. The surface of the hard-coating antiglare layer has an uneven shape and an arithmetic average surface roughness Ra in the range of 0.1 to 0.3 &#x3bc;m.

Hard-coated antiglare film, polarizing plate and image display including the same, method for producing the same, and method for evaluating the same

Provided herein are 2-phenoxy- and 2-phenylsulfonamide derivatives with CCR3 antagonistic activity. These compounds are useful for the treatment of diseases associated with CCR3 activity, including but not limited to, atopic dermatitis, allergic rhinitis, rheumatoid arthritis, Grave's disease, HIV infection, Alzheimer's disease, atherosclerosis and other inflammatory and/or immunological disorders.

2-phenoxy- and 2-phenylsulfonamide derivatives with CCR3 antagonistic activity for the treatment of inflammatory or immunological disorders

Growing community of inventors

Osaka, Japan

Naoki Tsuno